Cargando…
Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report
Eicosanoids are bioactive lipids derived from arachidonic acid, which have emerged as key regulators of a wide variety of pathophysiological processes in recent times and are implicated as mediators of gastrointestinal cancer. In this study, we investigated the systemic levels of lipoxygenase (LOX)-...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787076/ https://www.ncbi.nlm.nih.gov/pubmed/35087747 http://dx.doi.org/10.3389/fonc.2021.757073 |
_version_ | 1784639281151606784 |
---|---|
author | Blogowski, Wojciech Dolegowska, Katarzyna Deskur, Anna Dolegowska, Barbara Starzynska, Teresa |
author_facet | Blogowski, Wojciech Dolegowska, Katarzyna Deskur, Anna Dolegowska, Barbara Starzynska, Teresa |
author_sort | Blogowski, Wojciech |
collection | PubMed |
description | Eicosanoids are bioactive lipids derived from arachidonic acid, which have emerged as key regulators of a wide variety of pathophysiological processes in recent times and are implicated as mediators of gastrointestinal cancer. In this study, we investigated the systemic levels of lipoxygenase (LOX)-derived lipoxin A4 and B4, together with resolvin D1 and D2 in patients with pancreatic adenocarcinoma (n = 68), as well as in healthy individuals (n = 32). Systemic concentrations of the aforementioned immunoresolvents were measured using an enzyme-linked immunosorbent assay (ELISA). In this study, we observed that compared with concentrations in healthy individuals, the peripheral concentrations of the aforementioned eicosanoids were significantly elevated (2- to 10-fold) in patients with pancreatic cancer (in all cases p<0.00001). No significant association was observed between eicosanoid levels and the TNM clinical staging. Furthermore, we observed no significant differences in concentrations of the analyzed bioactive lipids between patients diagnosed with early-stage (TNM stage I-II) and more advanced disease (TNM stage III-IV). Receiver operating characteristic (ROC) curve analysis of each aforementioned immunoresolvent showed area under the curve values ranging between 0.79 and 1.00. Sensitivity, specificity, as well as positive and negative predictive values of the eicosanoids involved in the detection/differentiation of pancreatic adenocarcinoma ranged between 56.8% and 100%. In summary, our research is the first study that provides clinical evidence to support a systemic imbalance in LOX-derived lipoxins and resolvins as the mechanism underlying the pathogenesis of pancreatic adenocarcinoma. This phenomenon occurs regardless of the clinical TNM stage of the disease. Furthermore, our study is the first to preliminarily highlight the role of peripheral levels of immunoresolvents, particularly resolvin D1, as potential novel biomarkers of pancreatic cancer in humans. |
format | Online Article Text |
id | pubmed-8787076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87870762022-01-26 Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report Blogowski, Wojciech Dolegowska, Katarzyna Deskur, Anna Dolegowska, Barbara Starzynska, Teresa Front Oncol Oncology Eicosanoids are bioactive lipids derived from arachidonic acid, which have emerged as key regulators of a wide variety of pathophysiological processes in recent times and are implicated as mediators of gastrointestinal cancer. In this study, we investigated the systemic levels of lipoxygenase (LOX)-derived lipoxin A4 and B4, together with resolvin D1 and D2 in patients with pancreatic adenocarcinoma (n = 68), as well as in healthy individuals (n = 32). Systemic concentrations of the aforementioned immunoresolvents were measured using an enzyme-linked immunosorbent assay (ELISA). In this study, we observed that compared with concentrations in healthy individuals, the peripheral concentrations of the aforementioned eicosanoids were significantly elevated (2- to 10-fold) in patients with pancreatic cancer (in all cases p<0.00001). No significant association was observed between eicosanoid levels and the TNM clinical staging. Furthermore, we observed no significant differences in concentrations of the analyzed bioactive lipids between patients diagnosed with early-stage (TNM stage I-II) and more advanced disease (TNM stage III-IV). Receiver operating characteristic (ROC) curve analysis of each aforementioned immunoresolvent showed area under the curve values ranging between 0.79 and 1.00. Sensitivity, specificity, as well as positive and negative predictive values of the eicosanoids involved in the detection/differentiation of pancreatic adenocarcinoma ranged between 56.8% and 100%. In summary, our research is the first study that provides clinical evidence to support a systemic imbalance in LOX-derived lipoxins and resolvins as the mechanism underlying the pathogenesis of pancreatic adenocarcinoma. This phenomenon occurs regardless of the clinical TNM stage of the disease. Furthermore, our study is the first to preliminarily highlight the role of peripheral levels of immunoresolvents, particularly resolvin D1, as potential novel biomarkers of pancreatic cancer in humans. Frontiers Media S.A. 2022-01-11 /pmc/articles/PMC8787076/ /pubmed/35087747 http://dx.doi.org/10.3389/fonc.2021.757073 Text en Copyright © 2022 Blogowski, Dolegowska, Deskur, Dolegowska and Starzynska https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Blogowski, Wojciech Dolegowska, Katarzyna Deskur, Anna Dolegowska, Barbara Starzynska, Teresa Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report |
title | Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report |
title_full | Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report |
title_fullStr | Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report |
title_full_unstemmed | Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report |
title_short | Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report |
title_sort | lipoxins and resolvins in patients with pancreatic cancer: a preliminary report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787076/ https://www.ncbi.nlm.nih.gov/pubmed/35087747 http://dx.doi.org/10.3389/fonc.2021.757073 |
work_keys_str_mv | AT blogowskiwojciech lipoxinsandresolvinsinpatientswithpancreaticcancerapreliminaryreport AT dolegowskakatarzyna lipoxinsandresolvinsinpatientswithpancreaticcancerapreliminaryreport AT deskuranna lipoxinsandresolvinsinpatientswithpancreaticcancerapreliminaryreport AT dolegowskabarbara lipoxinsandresolvinsinpatientswithpancreaticcancerapreliminaryreport AT starzynskateresa lipoxinsandresolvinsinpatientswithpancreaticcancerapreliminaryreport |